-

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Hyliion Holdings Corp. (HYLN) Shareholders To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise Hyliion Holdings Corp. (“Hyliion” or the “Company”) (NYSE: HYLN) securities between May 12, 2026 and June 23, 2026, inclusive (the “Class Period”). Hyliion Holdings Corp. investors have until October 27, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR HYLIION HOLDINGS CORP. (HYLN), INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS

What Happened?

On June 23, 2026, Pelican Way Research issued a report entitled “Hyliion: A Glorified Science Project Who Has Continuously Failed to Meet Expectations And Is Now Throwing Around A Meaningless Deal.” The report alleged that a recent letter of intent the Company announced with VFG Holdings, LLC (“VFG”) for a major deal “is a sham” because VFG “does not appear to have any substance,” has a website that “contains just two pages” and appears to only have four employees. The report called into question whether VFG is an “AI data center integrator” capable of the deal previously announced by the Company.

On this news, the price of Hyliion stock fell $1.27 per share, or 17.2%, to close at $6.10 on June 23, 2026, thereby injuring investors. The following day, Hyliion stock fell another $1.18 per share, or 19.3%, to close at $4.92 on June 24, 2026, thereby injuring investors further.

What Is The Lawsuit About?

The complaint filed in this class action alleges that between May 12, 2026 and June 23, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) in order to cause rapid price appreciation in Hyliion stock, Defendants announced a deal with an entity that was very recently formed and does not appear to have any actual business operations; (2) the Individual Defendants timed the announcement and foregoing price appreciation to insider trade; and (3) as a result, Defendants’ statements about Hyliion’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Hyliion Holdings, Inc. securities between May 12, 2026 and June 23, 2026, you may move the Court no later than October 27, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Glancy Prongay Wolke & Rotter LLP

NYSE:HYLN

Release Versions

Contacts

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

More News From Glancy Prongay Wolke & Rotter LLP

Deadline Alert: Innventure, Inc. (INV) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 27, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Innventure, Inc. (“Innventure” or the “Company”) (NASDAQ: INV) securities between November 17, 2025 and August 13, 2026 inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR INNVENTURE, INC. INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY P...

Deadline Alert: XTI Aerospace, Inc. (XTIA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 27, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired XTI Aerospace, Inc. (“XTI Aerospace” or the “Company”) (NASDAQ: XTIA) securities between April 15, 2026 and August 17, 2026 inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR XTI AEROSPACE, INC. INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENT...

HIMS CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Hims & Hers Health, Inc. Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”)...
Back to Newsroom